Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan R Seckl

Showing results (1-10 of 210) with videos related to

Pageof 21
Sort By:
Progress in Brain Research|November 27, 2007
Glucocorticoids, developmental 'programming' and the risk of affective dysfunctionJonathan R Seckl
Current Opinion in Pharmacology|November 5, 2004
11beta-hydroxysteroid dehydrogenases: changing glucocorticoid actionJonathan R Seckl
European Journal of Endocrinology|November 24, 2004
Prenatal glucocorticoids and long-term programmingJonathan R Seckl
Drug Discovery Today|July 17, 2007
Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic targetMalgorzata Wamil, Jonathan R Seckl
Expert Review of Endocrinology & Metabolism|February 13, 2019
Glucocorticoid hormone programming in early-life and its impact on adult healthJonathan R Seckl, Eberhard Fuchs
Pediatric Endocrinology Reviews : PER|March 9, 2012
Transmission of programming effects across generationsAmanda J Drake, Jonathan R Seckl
Molecular and Cellular Endocrinology|January 18, 2006
The role of 11beta-hydroxysteroid dehydrogenases in the brainMegan C Holmes, Jonathan R Seckl
The Journal of Clinical Endocrinology and Metabolism|October 9, 2012
Antenatal glucocorticoid treatment: are we doing harm to term babies?Rebecca M Reynolds, Jonathan R Seckl
Expert Opinion on Therapeutic Targets|December 4, 2003
11beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative diseaseBrian R Walker, Jonathan R Seckl
Trends in Endocrinology and Metabolism: TEM|November 3, 2004
11beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memoryJonathan R Seckl, Brian R Walker
Pageof 21

Showing results (1-10 of 210) with videos related to

Sort By:
Pageof 21
Progress in Brain Research|November 27, 2007
Glucocorticoids, developmental 'programming' and the risk of affective dysfunctionJonathan R Seckl
Current Opinion in Pharmacology|November 5, 2004
11beta-hydroxysteroid dehydrogenases: changing glucocorticoid actionJonathan R Seckl
European Journal of Endocrinology|November 24, 2004
Prenatal glucocorticoids and long-term programmingJonathan R Seckl
Drug Discovery Today|July 17, 2007
Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic targetMalgorzata Wamil, Jonathan R Seckl
Expert Review of Endocrinology & Metabolism|February 13, 2019
Glucocorticoid hormone programming in early-life and its impact on adult healthJonathan R Seckl, Eberhard Fuchs
Pediatric Endocrinology Reviews : PER|March 9, 2012
Transmission of programming effects across generationsAmanda J Drake, Jonathan R Seckl
Molecular and Cellular Endocrinology|January 18, 2006
The role of 11beta-hydroxysteroid dehydrogenases in the brainMegan C Holmes, Jonathan R Seckl
The Journal of Clinical Endocrinology and Metabolism|October 9, 2012
Antenatal glucocorticoid treatment: are we doing harm to term babies?Rebecca M Reynolds, Jonathan R Seckl
Expert Opinion on Therapeutic Targets|December 4, 2003
11beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative diseaseBrian R Walker, Jonathan R Seckl
Trends in Endocrinology and Metabolism: TEM|November 3, 2004
11beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memoryJonathan R Seckl, Brian R Walker
Pageof 21